AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cambium Bio Limited

0.270

-0.005-1.82%

Volume:10.00K

Turnover:2.70K

Market Cap:4.94M

PE:-180.00

High:0.270

Open:0.270

Low:0.270

Close:0.275

Loading ...

Overview Company News Filings

China’s 2025H1 GDP Growth Beats Target — But Weak Domestic Demand Could Push CPI Into Deflation in 2025

BUZZ-Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug

BRIEF-Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate Ocular

Cambium Bio Ltd - Clears US FDA Regulatory Hurdles to Commence Phase 3 Dosing for Elate Ocular

THOMSON REUTERS

Cambium Bio Clears FDA Regulatory Hurdles-CMB.AX

Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial

MT Newswires Live

Cambium Bio Receives Ethics Approvals-CMB.AX

BRIEF-Cambium Bio Says Chair Barry Sechos Retires

Cambium Bio Chairman Retires

MT Newswires Live

Cambium Bio Ltd - Barry Sechos Retires as Chairman

THOMSON REUTERS

Cambium Bio Ltd - Edmund Waller Appointed as New Chairman

THOMSON REUTERS

Cambium Bio Says FDA Approves Potency Assay Strategy

BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol

Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol

Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular

The Market Herald

Cambium Bio Ltd - FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.27,"timestamp":1753148562338,"preClose":0.275,"halted":0,"volume":10000,"delay":0,"nameEN":"Cambium Bio Limited","floatShares":4291164,"shares":18282666,"eps":-0.0015,"marketStatus":"Trading","change":-0.005,"latestTime":"07-22 12:00:27 AEST","open":0.27,"high":0.27,"low":0.27,"amount":2700,"amplitude":0,"askPrice":0.27,"askSize":615,"bidPrice":0.26,"bidSize":4334,"shortable":3,"etf":0,"ttmEps":-0.0015,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753164000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.275,"openAndCloseTimeList":[[1753142400000,1753164000000]],"volumeRatio":2.313967,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","floatShares":4291164,"roa":"--","roe":"--","lyrEps":-0.005504,"volumeRatio":2.313967,"shares":18282666,"dividePrice":0,"high":0.27,"amplitude":0,"preClose":0.275,"low":0.27,"week52Low":0.19,"pbRate":"--","week52High":0.68,"institutionHeld":0,"latestPrice":0.27,"committee":0.751465,"eps":-0.0015,"divideRate":0,"volume":10000,"delay":0,"ttmEps":-0.0015,"open":0.27,"prevYearClose":0.4,"prevWeekClose":0.28,"prevMonthClose":0.21,"prevQuarterClose":0.21,"fiveDayClose":0.27,"twentyDayClose":0.2,"sixtyDayClose":0.225},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551152793","title":"China’s 2025H1 GDP Growth Beats Target — But Weak Domestic Demand Could Push CPI Into Deflation in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2551152793","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551152793?lang=en_us&edition=fundamental","pubTime":"2025-07-15 16:33","pubTimestamp":1752568411,"startTime":"0","endTime":"0","summary":"TradingKey - Driven by proactive macroeconomic policies, China’s Q2 GDP grew 5.2% year-over-year, slightly below Q1’s 5.4% but still above market expectations of 5.1%. For the first half of 2025, GDP expanded 5.3%, reaching a total value of ¥66.05 trillion. Despite Trump’s tariff war and global ","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20231130/ad307b1b3bd32a0f9f82b14e73cf5639.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20231130/ad307b1b3bd32a0f9f82b14e73cf5639.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/economic-indicator/250890177-china-economy-gdp-2025-export-consumer-deflation-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2550053106","title":"BUZZ-Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2550053106","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550053106?lang=en_us&edition=fundamental","pubTime":"2025-07-11 09:48","pubTimestamp":1752198531,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug** Shares of Cambium Bio CMB.AX up as much as 30.2% to A$0.28, hitting highest level since April 24** Regenerative medicine maker says it cleared US FDA's regulatory requirements to initiate patient dosing in its Phase 3 clinical trials of Elate Ocular which can be used to treat dry eye disease** About 93,600 shares change hands, 18x the 30-day average ** Stock down 30% YTD, at current levels  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nL6N3T801W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2550722366","title":"BRIEF-Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2550722366","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550722366?lang=en_us&edition=fundamental","pubTime":"2025-07-11 08:05","pubTimestamp":1752192343,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate OcularJuly 11 (Reuters) - Cambium Bio Ltd CMB.AX:CLEARS US FDA REGULATORY HURDLES TO COMMENCE PHASE 3 DOSING FOR ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nFWN3T70O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2550674984","title":"Cambium Bio Ltd -  Clears US FDA Regulatory Hurdles to Commence Phase 3 Dosing for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2550674984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550674984?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:10","pubTimestamp":1752189038,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T70O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2550674089","title":"Cambium Bio Clears FDA Regulatory Hurdles-CMB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550674089","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550674089?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:10","pubTimestamp":1752189018,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASXbY1k96","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX2vXy3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2547424052","title":"Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2547424052","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547424052?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:19","pubTimestamp":1751267960,"startTime":"0","endTime":"0","summary":"Cambium Bio  secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","BK7067","CMB.AU","XKO.AU"],"gpt_icon":0},{"id":"2547803325","title":"Cambium Bio Receives Ethics Approvals-CMB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547803325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547803325?lang=en_us&edition=fundamental","pubTime":"2025-06-30 07:23","pubTimestamp":1751239387,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250629:nASXcL5CZ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250629:nASXbrZS2p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2537772686","title":"BRIEF-Cambium Bio Says Chair Barry Sechos Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2537772686","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537772686?lang=en_us&edition=fundamental","pubTime":"2025-05-21 13:14","pubTimestamp":1747804459,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says Chair Barry Sechos RetiresMay 21 (Reuters) - Cambium Bio Ltd CMB.AX:BARRY SECHOS RETIRES AS CHAIRMANEDMUND WALLER APPOINTED AS NEW CHAIRMANFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RS1WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2537559674","title":"Cambium Bio Chairman Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2537559674","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537559674?lang=en_us&edition=fundamental","pubTime":"2025-05-21 11:55","pubTimestamp":1747799711,"startTime":"0","endTime":"0","summary":"Cambium Bio (ASX:CMB) Chairman Barry Sechos will retire from the board on Wednesday after 13 years of service, according to a same-day filing with the Australian bourse.Executive director and Chief Scientific Officer Edmund Waller will take over the chairman position, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7067","CMB.AU","XKO.AU","XAO.AU"],"gpt_icon":0},{"id":"2537766006","title":"Cambium Bio Ltd - Barry Sechos Retires as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2537766006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537766006?lang=en_us&edition=fundamental","pubTime":"2025-05-21 10:32","pubTimestamp":1747794755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RS1WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2537676607","title":"Cambium Bio Ltd - Edmund Waller Appointed as New Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2537676607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537676607?lang=en_us&edition=fundamental","pubTime":"2025-05-21 10:32","pubTimestamp":1747794755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RS1WI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2520763447","title":"Cambium Bio Says FDA Approves Potency Assay Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520763447","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520763447?lang=en_us&edition=fundamental","pubTime":"2025-03-18 09:05","pubTimestamp":1742259956,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - Cambium Bio Ltd ::*FDA APPROVES CAMBIUM BIO'S POTENCY ASSAY STRATEGY FOR ELATE OCULAR PHASE 3 CLINICAL TRIALS*Further company coverage: CMB.AX* ((Reuters.Briefs@thomsonreuters.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nRSD806ZCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514303111","title":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303111?lang=en_us&edition=fundamental","pubTime":"2025-02-25 13:09","pubTimestamp":1740460163,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial ProtocolFeb 25 (Reuters) - Cambium Bio Ltd CMB.AX:FDA APPROVES ELATE OCULAR PHASE 3 CLINICAL TRIAL PROTOCOLFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514039295","title":"Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514039295","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514039295?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:38","pubTimestamp":1740458334,"startTime":"0","endTime":"0","summary":"Cambium Bio  has received approval from the US Food and Drug Administration  for a protocol relating to Phase 3 clinical trials of its Elate Ocular treatment for moderate-to-severe dry eye disease.The approval represents a key milestone in advancing Elate Ocular towards market registration and follows the FDA granting the product fast-track designation in December.Fast-tracking helps expedite the review of drugs that treat serious conditions and address unmet medical needs.Chief executive officer Karolis Rosickas said the Phase 3 protocol was pivotal to the development of the Elate Ocular trials.“The trial design reflects extensive consultation with regulatory experts and key opinion leaders to ensure we meet FDA requirements for registration,” he said.The fast-track designation will enable Cambium to have more frequent interactions with the FDA throughout Elate Ocular’s development process and makes the product eligible for potential accelerated approvals and priority reviews.“With fa","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/cambium-bio-us-fda-approval-phase-3-elate-ocular-dry-eye-disease-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2514708970","title":"Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708970","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514708970?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:37","pubTimestamp":1740443820,"startTime":"0","endTime":"0","summary":"Cambium Bio  has flagged approval from the U.S. FDA for phase three of a clinical trial using its Elate Ocular product to treat moderate to severe dry eye disease.The market clearly liked the news – Cambium jumped more than 40% in the second hour of trade; the latest winner in a small basket of biotech stocks progressing towards late-stage approvals and commercialisation.In Cambium’s own words, the Phase 3 trial represents a final step towards market registration for its Elate Ocular product, with the third trial typically being the final in the FDA’s approval ringer. The Phase 3 program is ultimately geared to acquire a Biologics Licence Application . Trial sites in both the U.S. and Australia – “and select other countries” – will constitute Phase 3; Cambium won FDA Fast Track designation for Elate last December.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cambium-jumps-43-as-fda-approves-phase-3-trial-for-elate-ocular-2025-02-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514670775","title":"Cambium Bio Ltd -  FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670775?lang=en_us&edition=fundamental","pubTime":"2025-02-25 07:15","pubTimestamp":1740438945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMB.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-07-04","symbol":"CMB.AU","defaultRemindTime":1720051200000,"type":"split","dateTimestamp":1720015200000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMB.AU\",market:\"AU\",,,undefined,":[]}}